Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)

(2014) Qin Ning et al.   JOURNAL OF HEPATOLOGY

O113 COMBINATION THERAPY WITH PEGINTERFERON ALFA-2a AND A NUCLEOS(T)IDE ANALOGUE FOR HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: RESULTS OF A LARGE, RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

(2014) W.-W. Su et al.   JOURNAL OF HEPATOLOGY

Current developments in nucleoside/nucleotide analogues for hepatitis B

(2014) Angeline Oi-Shan Lo et al.   Expert Review of Gastroenterology & Hepatology

Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment

(2013) Grace Lai–Hung Wong et al.   GASTROENTEROLOGY

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis

(2013) Grace Lai-Hung Wong et al.   HEPATOLOGY

Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion

(2013) Zhen Huan Cao et al.   Journal of Digestive Diseases

Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential

(2013) Masaru Enomoto et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study

(2013) Z. Huang et al.   JOURNAL OF VIRAL HEPATITIS

Chronic Hepatitis B: A Treatment Update

(2013) Vincent Wong et al.   SEMINARS IN LIVER DISEASE

A randomized controlled trial of sequential peginterferon-alpha and telbivudine or vice versa for 48 weeks in HBeAg-negative chronic hepatitis B

(2012) Paola Piccolo et al.   ANTIVIRAL THERAPY

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

(2012) Yun-Fan Liaw et al.   Hepatology International

Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B

(2012) Jens M. Kittner et al.   JOURNAL OF CLINICAL VIROLOGY

Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B

(2012) Masaru Enomoto et al.   JOURNAL OF GASTROENTEROLOGY

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

(2012) Vincent Rijckborst et al.   JOURNAL OF HEPATOLOGY

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa

(2012) Yun-Xia Wang et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy

(2011) Y. Liang et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients

(2011) Henry L-Y Chan et al.   ANTIVIRAL THERAPY

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

(2011) Akihiro Matsumoto et al.   HEPATOLOGY RESEARCH

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

(2011) Henry Lik-Yuen Chan et al.   JOURNAL OF HEPATOLOGY

Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B

(2010) G. L.-H. Wong et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B

(2010) Jurriën G.P. Reijnders et al.   GASTROENTEROLOGY

13 TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B – VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN)

(2010) P. Marcellin et al.   JOURNAL OF HEPATOLOGY

Cytokines: their pathogenic and therapeutic role in chronic viral hepatitis

(2010) J. R. Larrubia et al.   REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS

A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B

(2009) Paola Piccolo et al.   ANTIVIRAL THERAPY

Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues

(2009) Erik H.C.J. Buster et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Predictors of Treatment Response in Chronic Hepatitis B

(2009) Grace L.-H. Wong et al.   DRUGS

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

The replication cycle of hepatitis B virus

(2009) Stephan Urban et al.   JOURNAL OF HEPATOLOGY

Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma

(2008) J. J. Y. SUNG et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection

(2008) Nobukazu Yuki et al.   JOURNAL OF GASTROENTEROLOGY

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

(2008) Jessica Tan et al.   JOURNAL OF HEPATOLOGY